NCT07067112Recruiting
Suppressive Functions of Regulatory T Cells in Migraine
Source: ClinicalTrials.gov · Last updated 14 Oct 2026
Brief summary (registry, in English)
Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and/or inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis. The investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 4 Jul 2025
- Start date
- 10 Sept 2026
- Primary completion date
- 30 Nov 2027
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Migraine
- NCT number
- NCT07067112
What you commit to
- Study type: Interventional
- Planned participants: 24
- From 10 Sept 2026 to the primary completion date, 30 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy, delivery, miscarriage, breastfeeding, participation in a medically assisted human reproduction program (ovary stimulation/hormone therapy) \< 3 months before blood sampling
- Modification of prophylactic anti-migraine therapy (start, change of molecule, interruption) \< 1 month before blood sampling (for migraine participants)
- Hormone therapy (beside contraception and treatment of endometriosis)
- Transplantation (solid organ or bone marrow)
Other illness
- Diagnosis or suspicion of type 2 diabetes, auto-immune or inflammatory diseases, immunodeficiency diseases
- Cancer (active or remitting) \< 1 year before blood sampling (solid organ or blood)
- Haematologic disease (benign or malignant) of the lymphoid lineage
- For controls : history of migraine
Other
- BMI \< or = 17kg/m² or \> or = 30kg/m²
- Diagnosis of headache of non-migraine origin, except for tension type headache (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)
- For controls participants : tension type headache with 4 or more monthly headache days
- Menopause, hysterectomy, or bilateral oophorectomy
- Guardianship, curatorship, safeguard of justice or deprivation of liberty
Who the study is looking for
- Females
- 18 to 50 years old
- For chronic migrain : At least 8 monthly migraine days
Age in the registry: 18 years to 50 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.